These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 3146822)

  • 21. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
    Fleury V; Lijnen HR; Anglés-Cano E
    J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR; Van Hoef B; Nelles L; Collen D
    J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
    Fischer BE
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J; Yu M; Ru B
    Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
    Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
    Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes.
    Lee SG; Kalyan N; Wilhelm J; Hum WT; Rappaport R; Cheng SM; Dheer S; Urbano C; Hartzell RW; Ronchetti-Blume M
    J Biol Chem; 1988 Feb; 263(6):2917-24. PubMed ID: 3125172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    Biochim Biophys Acta; 1986 Dec; 884(3):402-8. PubMed ID: 3778931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Nelles L; Holmes WE; Collen D
    Eur J Biochem; 1988 Feb; 172(1):185-8. PubMed ID: 2894309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation of Arg154 to Gly154 in urokinase augments its fibrin-specificity.
    Peng G; Ma Z; Kuai L; Zhu D
    Biochem Mol Biol Int; 1997 Apr; 41(5):887-94. PubMed ID: 9137818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.